Corporate Overview


Our lead product: EGRIFTA®
Our lead product, EGRIFTA® (tesamorelin for injection), is the first and only treatment approved by the U.S. Food and Drug Administration indicated to reduce excess abdominal fat in HIV-infected patients with lipodystrophy.

EGRIFTA® is exclusively commercialized in the United States by EMD Serono, Inc. pursuant to a collaboration and licensing agreement. EGRIFTA® is the proposed brand name to be used globally.